SILENCING THE UNDRUGGABLE: Silexion's SIL204 Unleashes Breakthrough Against Deadly Cancers!
- Silexion Therapeutics' SIL204 shows stunning preclinical success against pancreatic, colorectal, and lung cancer cells.
- The next-gen RNAi therapy effectively neutralizes the notorious KRAS G12D mutation, a key driver of aggressive tumors [1, 4].
- This breakthrough dramatically expands SIL204's therapeutic horizon, offering new hope against cancers with huge unmet needs5.
GRAND CAYMAN, Cayman Islands – May 29, 2025 – In a seismic announcement that could reshape the fight against some of the deadliest cancers, Silexion Therapeutics (NASDAQ: SLXN) today unveiled compelling preclinical data for its next-generation RNAi therapeutic, SIL204. The results are nothing short of groundbreaking, demonstrating SIL204's potent efficacy against human pancreatic, colorectal, and non-small-cell lung cancer (NSCLC) cell lines harboring the formidable KRAS G12D mutation1.
For too long, KRAS mutations—found in roughly 90% of pancreatic, 45% of colorectal, and 35% of non-squamous NSCLC cancers—have been a near-impregnable fortress, rendering many conventional treatments ineffective4. Now, SIL204, armed with an enhanced lipid-conjugated delivery system, is punching through these defenses, effectively inhibiting cancer cell proliferation and metabolic activity at extremely low doses. Notably, in GP2D colorectal cancer cells, SIL204 achieved an astonishing inhibition rate of approximately 90%5.
"These results represent a significant expansion of SIL204's potential," declared Ilan Hadar, Chairman and CEO of Silexion. "The data demonstrates SIL204's enhanced delivery system enables potent activity... across a range of KRAS-driven solid tumors."
This isn't just about one cancer type; it's about a potential paradigm shift. SIL204's success across pancreatic (Panc-1), colorectal (GP2D), and lung (A427) cancer cell lines suggests it could be a powerful pan-KRAS therapy [1, 5].
Dr. Mitchell Shirvan, Silexion's Chief Scientific Officer, emphasized the revolutionary approach: "By silencing KRAS at the RNA level, SIL204 addresses the fundamental genetic driver of these aggressive cancers, potentially overcoming resistance mechanisms."
With KRAS-driven cancers representing a global market exceeding $30 billion annually and a profound unmet medical need, SIL204's promise is monumental4. Silexion is now poised to conduct further studies, including a focused look at lung cancer cell lines, fueling hope that this innovative RNAi therapy could soon bring a powerful new weapon to patients battling these devastating diseases5.
References
Stay Updated!
Get the latest biotech and pharma news delivered to your inbox.